How long does teduglutide take to work?

Response is gradual. Most patients show reductions in parenteral nutrition volume within 12-24 weeks. Some may require up to 6 months. Approximately 20-30% achieve complete independence, which can take 1-2 years. Treatment should be stopped if no benefit after 6 months.

Why does teduglutide require colonoscopy monitoring?

GLP-2 is a trophic hormone that promotes intestinal mucosal growth. In preclinical studies, very high doses caused intestinal polyp growth in rodents. While no increased cancer risk has been observed in humans, the FDA requires baseline colonoscopy with polyp removal before starting, and surveillance every 1-2 years during treatment.

Treatment hubFDA ApprovedDeep Dive

Teduglutide Treatment Guide: Gattex, Cost and Provider Paths

In the United States, Teduglutide is an FDA-approved peptide therapy. Short bowel syndrome in adult and pediatric patients who are dependent on parenteral support

Published: Apr 27, 2026Updated: Apr 27, 2026Medically reviewed: Apr 27, 2026Current

Medically Reviewed

This content was medically reviewed by James Patterson, MD, Board-Certified in Sports Medicine and Physical Medicine & Rehabilitation.

Last reviewed: April 27, 2026

Overview

Teduglutide is a recombinant analog of human GLP-2 and the first FDA-approved therapy for short bowel syndrome (SBS) dependent on parenteral support. It promotes intestinal growth and adaptation, reducing the need for intravenous nutrition.

Approved Product Paths

Gattex

Branded teduglutide pathway. Short bowel syndrome in adult and pediatric patients who are dependent on parenteral support

Benefits

•Only FDA-approved drug for short bowel syndrome
•Reduces parenteral nutrition volume requirements by ~30-50%
•Achieves parenteral nutrition independence in ~20-30% of patients
•Improves intestinal absorption and mucosal architecture

Side Effects & Friction

•Abdominal pain and distension
•Nausea and vomiting
•Upper respiratory tract infection
•Injection site reactions

Administration Routes

Subcutaneous injection

Cost Reality

Teduglutide costs vary by brand, pharmacy, and insurance design. As an FDA-approved medication, coverage may be available but often requires prior authorization and documentation of the approved indication.

Provider Path

The highest-value next step is finding a provider experienced in healing & recovery who can evaluate whether Teduglutide fits the patient's clinical profile and insurance constraints.

How Teduglutide Works

Teduglutide is a recombinant 33-amino-acid analog of glucagon-like peptide-2 (GLP-2). It promotes intestinal growth, increases nutrient and fluid absorption, and reduces parenteral nutrition dependence in short bowel syndrome.

Teduglutide is a recombinant analog of human GLP-2 with a single amino acid substitution (alanine to glycine at position 2). This modification confers resistance to dipeptidyl peptidase-4 (DPP-4) degradation, extending half-life from minutes to hours.

GLP-2 receptors are expressed on intestinal epithelial cells, subepithelial myofibroblasts, and enteric neurons. Activation stimulates crypt cell proliferation, reduces apoptosis, and increases villus height and crypt depth.

The net effect is increased intestinal mucosal surface area, enhanced nutrient and fluid absorption, and improved intestinal barrier function. In short bowel syndrome, this can reduce or eliminate the need for parenteral nutrition.

Teduglutide also increases splanchnic blood flow, enhances intestinal motility patterns, and may improve bile acid absorption. These effects complement the trophic action.

The drug is administered as a daily subcutaneous injection. Benefits typically emerge over weeks to months as intestinal adaptation progresses.

Teduglutide does not cure short bowel syndrome but enhances the natural intestinal adaptation process that occurs after massive resection.

GLP-2 receptorIntestinal epithelial cellsEnteric neuronsSubepithelial myofibroblasts

Clinical Trial Evidence

pivotal SBS trial

PMID: 21073315

Population: Adults with short bowel syndrome dependent on parenteral nutrition

N= 83

Duration: 24 weeks

Endpoint: ≥20% reduction in parenteral nutrition volume at week 20 and 24

63% achieved ≥20% PN reduction vs 30% placebo (p=0.002)
27% achieved complete PN independence
Reduced stool frequency and improved hydration
Benefit sustained in open-label extension

STEPS 2 (long-term extension)

PMID: 23247105

Population: Patients completing initial 24-week trial

N= 52

Duration: 28 additional weeks (52 total)

Endpoint: Sustained PN reduction and safety

PN reductions sustained at 52 weeks
No new safety signals with extended therapy
Some patients achieved further PN weaning over time

Dosing & Administration

Short bowel syndrome (Gattex)Subcutaneous · Once daily

Starting: 0.05 mg/kg once daily

Titration: No titration; weight-based fixed dose

Maintenance: 0.05 mg/kg once daily

Maximum: 0.05 mg/kg once daily

•Reconstitute with provided diluent
•Inject subcutaneously into abdomen, thigh, or upper arm; rotate sites
•Take at same time each day
•Requires REMS program enrollment due to cancer risk concern
•Monitor for intestinal obstruction and gallbladder/biliary disease

Side Effect Profile

Common

Abdominal painmild30%

Usually mild; may reflect intestinal adaptation

Injection site reactionsmild25%

Erythema, pain; rotate sites

Nauseamild20%

Usually transient

Headachemild15%

Mild

Upper respiratory infectionmild15%

Likely unrelated

Serious

Intestinal obstructionsevere2-3%

Monitor for signs; may require temporary discontinuation

Biliary/pancreatic diseasesevere2%

Cholecystitis, cholangitis, pancreatitis reported; requires monitoring

Fluid overloadmoderateRare

Increased fluid absorption may cause edema in susceptible patients

Contraindications & Warnings

Do Not Use

Active or suspected malignancy (theoretical concern due to trophic effects on GI mucosa)
History of colorectal cancer or polyps
Known or suspected mechanical GI obstruction
Hypersensitivity to teduglutide

Important Warnings

REMS program required: due to theoretical risk of cancer from intestinal mucosal proliferation, prescribers, pharmacies, and patients must enroll in REMS.
Cancer risk: GLP-2 is trophic. Avoid in patients with active malignancy or history of colorectal cancer/polyps. Monitor for polyps with colonoscopy before starting and every 1-2 years.
Intestinal obstruction: may occur due to mucosal growth and stenosis. Monitor for symptoms.
Biliary and pancreatic disease: cholecystitis, cholangitis, and pancreatitis reported. Monitor liver enzymes, bilirubin, and amylase/lipase.
Fluid overload: increased absorption may cause peripheral edema or heart failure exacerbation.

Drug Interactions

Drug	Interaction	Severity	Mechanism
None significant	Minimal systemic interaction profile	minor	Peptide metabolized by proteolysis; not CYP-dependent

Monitoring Requirements

Colonoscopy before initiation and every 1-2 years (REMS requirement)
Parenteral nutrition volume and oral intake weekly during titration
Weight, fluid balance, and signs of edema
Liver enzymes and bilirubin every 3-6 months
Amylase and lipase if abdominal symptoms
Signs of intestinal obstruction
Electrolytes and nutritional status

How Teduglutide Compares

EfficacyTeduglutide advantage

Teduglutide: 63% achieved ≥20% PN reduction

Glutamine supplementation: Modest benefit in some studies

Teduglutide is the only FDA-approved drug for SBS with robust RCT data

InvasivenessTeduglutide advantage

Teduglutide: Daily injection

Intestinal transplantation: Major surgery with lifelong immunosuppression

Teduglutide is far less invasive; transplant reserved for intestinal failure with life-threatening complications

OutcomesTeduglutide advantage

Teduglutide: Reduced PN dependence, improved quality of life

Standard care (PN alone): Lifelong PN with complications

Teduglutide meaningfully improves SBS natural history

Evidence Quality Assessment

Overall Evidence Grade: B

A = Strong evidence from multiple large RCTs

Human RCTs: Moderate: Pivotal trial n=83 (small due to rare disease); well-controlled

Long-term data: Moderate: 52-week STEPS 2 data; longer-term registry ongoing

Real-world evidence: Growing: Post-marketing REMS registry accumulating data

Regulatory status: FDA-approved for short bowel syndrome in adults and children ≥1 year via REMS program

Is Teduglutide Right for You?

Ideal Candidates

Adults and children ≥1 year with short bowel syndrome dependent on parenteral nutrition
Patients with stable SBS who have completed intestinal adaptation period (typically >1 year post-resection)
Those motivated to reduce or eliminate PN dependence
Patients without history of colorectal cancer or active GI malignancy

Avoid

Active or recent GI malignancy
History of colorectal polyps or cancer
Mechanical GI obstruction
Patients unable to comply with REMS monitoring and colonoscopy requirements
Unstable SBS with active sepsis or severe malabsorption

Use With Caution

History of gallbladder or pancreatic disease
Heart failure (fluid overload risk)
Renal impairment
Patients on high-volume PN (may need slower weaning)

Cost & Insurance Deep Dive

List Price (Monthly)

~$25,000-$35,000/month

Cash-Pay Range

$25,000-$35,000/month

Insurance Coverage Rate

~80-90% with proper SBS diagnosis and REMS enrollment

Prior Auth Likelihood

Extremely high; requires SBS documentation, PN dependence verification, and REMS enrollment

Savings Programs

Gattex OneSource patient supportCopay assistance and navigation support

Eligibility: All patients

Coordinates insurance, REMS, and specialty pharmacy

Patient assistanceMay provide medication at reduced or no cost

Eligibility: Uninsured/underinsured

Case-by-case

Cost-Effectiveness Notes

•Extremely high cost but may be offset by reduced PN costs ($50,000-$150,000/year) and complication reductions
•Complete PN independence eliminates ongoing infusion supply and nursing costs
•Cost per quality-adjusted life year is favorable when PN reduction is achieved
•REMS program adds administrative burden but ensures safety monitoring

Ready to find a teduglutide provider?

Use the provider matcher to compare treatment paths by state, coverage, budget, urgency, and intake mode before committing to a prescribing workflow.

Find a teduglutide provider

Progress Tracking Tools

Monitor health markers and outcomes during treatment.

Smart WiFi Body Scale

Tracks BMI, body fat %, and muscle mass — essential for monitoring GLP-1 progress over time.

$30–60View on Amazon

Digital Kitchen Food Scale

Precise gram-level portion tracking helps maximize weight loss results on GLP-1 therapy.

$10–20View on Amazon

Protein Shaker Bottle Set

Leak-proof mixing bottles for protein shakes — supports consistent protein intake on a smaller appetite.

$12–25View on Amazon

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Teduglutide FAQ

Sources

1. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
Gut • 2005
Claim type: clinical
View source →
2. FDA Information on Teduglutide
FDA • 2026
Claim type: regulatory
View source →

This content is for informational purposes only and does not constitute medical advice.